Abstract:The third Sustainable Development Goal (SDG), to ensure healthy lives and promote well-being for all at all ages, has particular relevance and implementation challenges amongst people living with rare diseases such as cystic fibrosis (CF). Although the treatment and projected outcome of CF has significantly improved with the advent of CF transmembrane conductance regulator protein modulator (CFTRm) therapy, there remains significant global inequality with regards to access to these life-saving and life-altering drugs. Elexacaftor, tezacaftor, and ivacaftor (ETI) triple combination therapy, first licensed in the United States in 2019, has rapidly become the standard of care for children aged 6 years and older in most high-income countries for individuals with CFTR variants responsive to ETI. Negotiated agreements for access to ETI are currently in place in North America,Europe, Israel ,Australia and New Zealand. However, less priority has been given to negotiate agreements for access to CFTRm in low-middle income countries(LMIC) with significant CF populations such as Central and South America, India, the Middle East, and Southern Africa. These countries and individuals living with CF are therefore effectively being left behind, in direct conflict with the stated principle of the 2030 SDGs. In this review, we highlight the current global inequity in access to CFTRm drugs and its impact on widening disparities between high-income countries and LMIC in CF outcomes and survival. We further discuss the reasons for this inequity and explore the ethical- and human rights-based principles and dilemmas that clinicians, families, governments, and healthcare funders must consider when prioritizing fair and affordable access to expensive CFTRm drugs. Lastly, we propose possible solutions to overcoming the barriers to accessing affordable CFTRm drugs in LMIC and illustrate with examples how access to drug therapies for other conditions have been successfully negotiated in LMIC through innovative partnerships between governments and pharmaceutical industries.

Challenges in the care of cystic fibrosis in low‐to‐middle income countries

Diagnosis and treatment of cystic fibrosis in India: What is at stake for developing countries?

Expanding the Impact of New Cystic Fibrosis Therapies in Low‐ and Middle‐Income Countries

Identifying disparities in pediatric cystic fibrosis care between low-middle and middle-high income countries in the Middle East

The future of cystic fibrosis: A global perspective

The burden of cystic fibrosis in North Africa

New drugs, new challenges in cystic fibrosis care

Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap!

Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians

Revamping of Chronic Respiratory Diseases in Low- and Middle-Income Countries

International disparities in diagnosis and treatment access for cystic fibrosis

Advances in Care and Outcomes for Children with Cystic Fibrosis

Hope in Every Breath: Navigating the Therapeutic Landscape of Cystic Fibrosis

Improving gastrointestinal health in children and young people with cystic fibrosis

Cystic fibrosis management in pediatric population—from clinical features to personalized therapy

A Rare Case of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutation on Exon 8 in a Patient Presenting With Recurrent Infections and Failure to Thrive

Until it's done for everyone: the role of CFTR modulator label expansion

Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes

Cystic fibrosis in the year 2020: A disease with a new face

Challenges in Management of Pediatric Chronic Myeloid Leukemia (pCML) in the Low-Middle Income Countries (LMICs): Insights from an International CML Foundation (iCMLf) Multi-National Survey

Exploring the complexity of cystic fibrosis (CF) and psychosocial wellbeing in the 2020s: Current and future challenges